Neil Gheewala, MD
Interventional Cardiology · Tucson, AZNPI 1952562647
Payments from drug & device makers
Across 557 payments — averaging $573.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$250K
- Abbott$46K
- Boston Scientific$18K
- Abiomed$1K
- Medtronic$875
- Novartis$601
- plus $3K from 25 others
What the payments were for
- Consulting fees$65,91647%
- Speaking & faculty fees$25,48818%
- Travel & lodging$33,25724%
- Food & beverage$15,82011%
- Education$190%
- Other$660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 199 | $249,863 |
| Abbott | 101 | $45,638 |
| Boston Scientific | 74 | $17,676 |
| Abiomed | 19 | $1,481 |
| Medtronic(2 entities) | 14 | $875 |
| Novartis | 43 | $601 |
| Shockwave Medical, Inc | 18 | $579 |
| Cvrx, Inc. | 9 | $421 |
| Philips North America LLC | 3 | $321 |
| Pfizer | 12 | $248 |
| E.r. Squibb & Sons, L.L.C. | 14 | $215 |
| Kestra Medical Technology Services, Inc. | 8 | $172 |
| Penumbra, Inc. | 1 | $166 |
| Novo Nordisk | 7 | $130 |
| Stemline Therapeutics Inc. | 1 | $114 |
| Impulse Dynamics (USA) Inc. | 1 | $111 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $93 |
| Biotronik Inc. | 2 | $91 |
| Chiesi USA, Inc. | 5 | $88 |
| Cardiva Medical, Inc. | 4 | $75 |
| Welch Allyn | 1 | $66 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| Lexicon Pharmaceuticals, Inc. | 2 | $35 |
| Johnson & Johnson | 2 | $32 |
| Amgen | 2 | $32 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Tactile Systems Technology Inc | 2 | $24 |
| Altathera Pharmaceuticals LLC | 1 | $22 |
| Itamar Medical Inc | 1 | $16 |
| W. L. Gore & Associates, Inc. | 1 | $13 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$64,562
- MitraClip System$16,436
- MitraClip$14,563
- GENERAL - THERAPIES$9,889
- Mitra Clip system$9,546
- LOTUS EDGE$4,238
- AMPLATZER$2,500
- EVOQUE$1,110
- Impella$926
- Watchman$852
- GENERAL VASCULAR ACCESS$603
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$532
- WATCHMAN Access System$502
- CoreValve Evolut$396
- SYNERGY$290
- Barostim Neo System$280
- PASCAL$258
- Assurity Pacemaker$243
- OPTIMIZER$221
- Indigo System$166
How this compares
$319,277 in reported general payments places this provider in the 90th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 253 | $326,086 |
| EntrestoSacubitril/Valsartan | 101 | $133,275 |
| XareltoRivaroxaban | 69 | $83,093 |
| JardianceEmpagliflozin | 46 | $57,337 |
| Repatha SureclickEvolocumab | 33 | $32,136 |
| BrilintaTicagrelor | 23 | $14,983 |
| FarxigaDapagliflozin Propanediol | 11 | $11,805 |
| Praluent PenAlirocumab | 14 | $6,945 |
| Repatha SyringeEvolocumab | 19 | $6,185 |
| Atorvastatin Calcium | 461 | $4,853 |
| Metoprolol Succinate | 372 | $4,676 |
| Prasugrel Hcl | 13 | $3,488 |
| Ranolazine ErRanolazine | 16 | $2,095 |
| ClopidogrelClopidogrel Bisulfate | 161 | $2,005 |
| Lisinopril | 266 | $1,728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $248 | $326,086253 claims |
| NovartisEntresto | $601 | $133,275101 claims |
| Johnson & JohnsonXarelto | $32 | $83,09369 claims |
| AstraZenecaBrilinta, Farxiga | $12 | $26,78834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Tucson
- Thomas WaggonerTucson$4.1M
- Ajay TuliTucson$705K
- Kapildeo LotunTucson$488K
- Ryan TsudaTucson$245K
- Michel CorbanTucson$106K
- Dexter de LeonTucson$90K
- William ThomasTucson$71K
- Brenda PeartTucson$66K
- Ranjith ShettyTucson$50K
- Santiago RamirezTucson$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.